We are live on ! Find out more
GNRX

VanEck Vectors Generic Drugs ETF
GNRX

Delisted

GNRX was delisted on the 4th of April, 2019.

Back to rankings

1 hedge funds and large institutions have $133K invested in VanEck Vectors Generic Drugs ETF in 2018 Q4 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

18% less capital invested

Capital invested by funds: $163K → $133K (-$29.9K)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
APA
1
American Portfolios Advisors
New York
$133K – – –

GNRX Hedge Fund Activity: Q4 2018 in Review

1 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in VanEck Vectors Generic Drugs ETF (GNRX) for Q4 2018, worth a combined $133K — down 18% from $163K a quarter earlier.

Fund positioning in GNRX was balanced in Q4 2018: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

  • 1 institutional investor held VanEck Vectors Generic Drugs ETF (GNRX) as of Q4 2018, unchanged from Q3 2018.
  • Funds reported $133K of VanEck Vectors Generic Drugs ETF stock for Q4 2018, down 18% quarter-over-quarter.
  • 0 funds opened new VanEck Vectors Generic Drugs ETF positions in Q4 2018 and 0 closed out.

Based on aggregated 13F filings for Q4 2018.